Volume 118, Issue 2 , Pages 428-433, August 2006
Localization of nerve growth factor and its receptors in the human nasal mucosa
Background
Nerve growth factor (NGF) is a pluripotent mediator, the levels of which are elevated in nasal lavage fluids of individuals with allergic rhinitis at baseline. Levels of NGF increase after allergen challenge.
Objective
In the current study, we tested the hypotheses that mast cells are the main source of human nasal NGF, and that NGF can potentially affect mucosal elements other than nerves.
Methods
Immunostaining with antibodies against NGF, tryptase, CD3, eosinophil cationic protein, and the high-affinity (tyrosine kinase A) and low-affinity (p75) receptors for NGF was performed by using human nasal turbinate sections.
Results
Double immunofluorescence staining demonstrated NGF in only 2% (median) (1.3, 2.3; 25th, 75th percentiles) of mast cells, 0.2% (0, 0.4) of T cells, but in 62.2% (56.5, 68) of activated eosinophils. With immunohistology, NGF expression was consistently strongest in the submucosal glands and lesser in the epithelial lining. Both high-affinity and low-affinity receptors for NGF were localized not only on nerves, as expected, but also on nasal epithelium, submucosal glands, and some interstitial cells, but not on vascular endothelium.
Conclusion
This study demonstrates that submucosal glands, nasal epithelium, and eosinophils constitute the major sources of NGF in the human nasal mucosa. That NGF receptors are found in cells other than nerves supports the notion that the role of this neurotrophin is broader than simple modulation of the sensorineural system.
Clinical implications
The distribution of NGF and its receptors and its established release during allergic reactions suggest that this factor participates in the pathophysiology of allergic rhinitis.
Key words: Nerve growth factor, TrkA, p75, NGF receptors, rhinitis, mast cells, eosinophils, submucosal glands, sensory nerves, epithelium
Abbreviations used: NGF, Nerve growth factor, pAb, Polyclonal antibody, TrkA, Tyrosine kinase A
Supported by grant K23 AI 01799-01 from the National Institutes of Health.Disclosure of potential conflict of interest: A. C. Myers has received grant support from the National Institutes of Health. A. Sanico has consultant arrangements with and has received grant support from Merck and is on the speaker's bureau for Aventis, GlaxoSmithKline, Merck, Pfizer, and UCB. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(06)00930-4
doi:10.1016/j.jaci.2006.04.037
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 118, Issue 2 , Pages 428-433, August 2006
